Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, Opt-in with us: www.register.msviewsandnews.org

Please visit our MS learning channel on YouTube, which provides hundreds of MS topics presented by MS Experts across the USA, from many of our video recorded education programs. Archived here: www.youtube.com/msviewsandnews -- PLUS Visit our Social media platforms: Facebook, Twitter, and Instagram

~~ Left side of this blog shows resources, needed by many. Easiest way to find topic or articles is to use our 'search by topic' tool, to find specific information ~~

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Tuesday, February 27, 2018

Ocrevus Significantly Decreases Disease Activity in MS Patients, Study Shows

FEBRUARY 27, 2017   - BY PATRICIA INACIO, PHD

Ocrevus (ocrelizumab), an investigational monoclonal antibody, significantly decreases disease activity in patients with multiple sclerosis (MS), and is associated with a higher proportion of patients reaching no evidence of disease activity (NEDA), according to a new analysis.
NEDA is a parameter that measures the absence of disease activity (in clinical settings and in magnetic resonance imaging) in MS patients. This parameter is increasingly recognized for its utility in clinical trials and is a potential goal for MS therapeutics.
READ MORE



:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

No comments: